All In Biotech

Drug Trial Radar · NCT00137111

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Last checked: Nov 20, 2026Latest source record: Sep 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 501 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

501

Actual

Start

Jul 8, 2000

Primary completion

Nov 2010

Study completion Apr 2014

Sponsor

Lead sponsor
St. Jude Children's Research HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Aug 29, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.

Conditions

  • Lymphoblastic Leukemia, Acute

Interventions

  • Prednisone, Dexamethasone, Vincristine, DaunorubicinDrug

    See Detailed Description sections for details on treatment interventions.

  • Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginaseDrug

    See Detailed Description sections for details on treatment interventions.

  • Methotrexate, Cyclophosphamide, Cytarabine, EtoposideDrug

    See Detailed Description sections for details on treatment interventions.

  • Mercaptopurine, ImatinibDrug

    See Detailed Description sections for details on treatment interventions.

  • chemotherapy, intrathecal chemotherapyProcedure

    See Detailed Description sections for details on treatment interventions.

  • steroid therapy, hematopoietic stem cell transplantationProcedure

    See Detailed Description sections for details on treatment interventions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Event-free Survival (EFS)Time frame: Median follow-up time (range) 5.6 (1.3 to 8.9) years
  2. Continuous Complete Remission Since Week 56 Therapy.Time frame: Median follow up time (range) 4.5 (1 to 7.8) years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • St Jude Children's Research Hospital

    Memphis, Tennessee

  • Cook Children's Medical Center

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.